Adicet Bio, Inc.
NASDAQ:ACET · NASDAQ Global Market
+$0.50 today
Vol 0.08M · Avg 0.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-73.4%
avg -28.8%
ROIC
-70.2%
avg -33.1%
ROA
-60.7%
avg -31.3%
Analysis
ROA is currently the strongest return metric at -60.7% versus its period average of -31.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chen Schor | Chief Executive Officer, President & Director | $953,668.00 | — | 54 | $468,555.00 | 5.01% |
Blake Aftab | Senior Vice President & Chief Scientific Officer | $731,122.00 | — | 45 | $72,555.00 | 0.78% |
Julie Maltzman | Chief Medical Officer | $622,198.00 | — | 58 | $72,555.00 | 0.78% |
Brian Nicholas Harvey | Chief Financial Officer | $611,141.00 | — | 65 | $43,361.00 | 0.46% |
Donald Healey | Chief Technology Officer | $606,337.00 | — | 64 | $43,361.00 | 0.46% |
Amy Locke | Chief Human Resource Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$6.60M
Sells
4
$674,847.06
Net Sentiment
+$5.93M
Net buying
Most Active
ORBIMED ADVISORS LLC
6 transactions
Analysis
Insiders reported 5 buys worth $6.60M and 4 sells worth $674,847.06 over the last 12 months. That adds up to net buying of $5.93M. ORBIMED ADVISORS LLC was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +17.2% | -2.1% (15yr)2 analysts |
| Revenue | N/A | N/A | +4.7% | -2.5% (15yr)3 analysts |
| Net Income | N/A | N/A | +19.5% | +8.0% (15yr)3 analysts |
| EBIT | N/A | N/A | +20.4% | +3.1% (15yr)3 analysts |
Analysis
Recent growth has been strongest in EBIT at +20.4% over three years. Forward estimates point to Net Income at +8.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Adagene Inc.
NASDAQ:ADAG
$134.41M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Lite Strategy, Inc.
LITS
$25.22M
CervoMed Inc.
CRVO
$22.68M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages ACET?
Adicet Bio, Inc. (ACET) lists 6 active executives. The top listed executive is Blake Aftab, Senior Vice President & Chief Scientific Officer.
Are ACET insiders buying or selling?
Recent insider activity shows net buying of $1.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.